Contrasting Enovis (NYSE:ENOV) & Schrodinger (NASDAQ:SDGR)

Enovis (NYSE:ENOV) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Enovis and Schrodinger, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1	0	6	2	3.00
Schrodinger	1	4	4	0	2.33

Enovis currently has a consensus price target of $47.43, suggesting a potential upside of 108.81%. Schrodinger has a consensus price target of $21.13, suggesting a potential upside of 83.38%. Given Enovis’ stronger consensus rating and higher probable upside, equities analysts clearly believe Enovis is more favorable than Schrodinger.

Volatility & Risk

Enovis has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Valuation and Earnings

This table compares Enovis and Schrodinger”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25 billion	0.58	-$1.18 billion	($20.71)	-1.10
Schrodinger	$255.87 million	3.32	-$103.26 million	($1.42)	-8.11

Schrodinger has lower revenue, but higher earnings than Enovis. Schrodinger is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

98.5% of Enovis shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 2.7% of Enovis shares are held by insiders. Comparatively, 21.0% of Schrodinger shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Enovis and Schrodinger’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enovis	-52.69%	8.74%	4.19%
Schrodinger	-40.37%	-29.47%	-14.69%

Summary

Enovis beats Schrodinger on 9 of the 15 factors compared between the two stocks.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.